Fate Therapeutics, Inc. (FATE) is a publicly traded Healthcare sector company. As of October 12, 2026, FATE trades at $2.19 with a market cap of $261.21M and a P/E ratio of -2.12. FATE moved +0.64% today. Year to date, FATE is +121.86%; over the trailing twelve months it is +35.40%. Its 52-week range spans $0.66 to $3.23. Analyst consensus is buy with an average price target of $6.63. Rallies surfaces FATE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Fate Therapeutics appoints Jamie Harrell as SVP of market development, commercial operations: Fate Therapeutics appointed Jamie Harrell senior vice president of market development and commercial operations, effective Oct. 12, 2026. He will lead commercial and market development strategy across autoimmunity and oncology as the company moves toward commercialization.
| Metric | Value |
|---|---|
| Price | $2.19 |
| Market Cap | $261.21M |
| P/E Ratio | -2.12 |
| EPS | $-1.05 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.23 |
| 52-Week Low | $0.66 |
| Volume | 232 |
| Avg Volume | 0 |
| Revenue (TTM) | $6.49M |
| Net Income | $-126.00M |
| Gross Margin | 0.00% |
6 analysts cover FATE: 0 strong buy, 3 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.63.